FDA Adcomm Backs Neuroblastoma Treatment, Even Without RCT Data

Despite the lack of a randomized controlled trial for the US WorldMeds’ investigational drug, an FDA advisory committee found that the company provided adequate data to support its benefit in high-risk neuroblastoma.

Related Keywords

Colorado , United States , , University Of Colorado , Gastrointestinal Medical Oncology Program , Oncologic Drugs Advisory Committee On , Drugs Advisory Committee , Resume , Careers , Da Adcomm Backs Neuroblastoma Treatment , Ven Without Rct Data , Iospace , Advice ,